#United States #NASDAQ #PTC Therapeutics #stock options #Warren, N.J.

PTC Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule

In a significant move aimed at enhancing its recruitment strategy, PTC Therapeutics, Inc. (NASDAQ: PTCT) has recently approved a series of inducement grants. On April 13, 2026, the company granted non-statutory stock options and restricted stock units (RSUs) to a newly hired non-executive employee, demonstrating its commitment to attracting top talent and strengthening its workforce.

Details of the Inducement Grants

The inducement grant consists of a total of 1,155 stock options and 925 RSUs. These stock options provide the opportunity to purchase the company's common stock, which is a valuable addition to the employee's compensation package. Each stock option has been set at an exercise price of $70.42 per share, reflecting the closing price of PTC's stock on the grant date. The award, approved by PTC's Compensation Committee, serves as a key incentive for the new employee's acceptance of employment, ensuring alignment with Nasdaq's Listing Rule 5635(c)(4).

These stock option awards come with a notable vesting schedule. They are structured to vest over a period of four years, with an initial 25% of the shares becoming available after the first year of service. The remaining shares will then vest at a rate of 6.25% every three months, contingent upon the employee remaining with the company through these vesting dates. Similarly, the RSUs will also vest over four years, with 25% vesting each year on the anniversary of the employee's hire date. This strategic approach not only incentivizes loyalty but also allows the employee to benefit from the company’s growth and success in the long term.

PTC Therapeutics at a Glance

PTC Therapeutics is a global biopharmaceutical organization devoted to the discovery and development of innovative medicines focused on rare disorders. The company’s mission revolves around delivering clinically differentiated therapies that can significantly improve the quality of life for patients, both children and adults, affected by such conditions. PTC is recognized for its robust pipeline of transformative treatments, which highlights its commitment to addressing unmet medical needs in the healthcare landscape.

By leveraging its scientific expertise and global access to commercial infrastructures, PTC aims to maximize value not just for patients, but also for all stakeholders involved. The company is determined to continue expanding its portfolio with cutting-edge research and innovative solutions relevant to the biopharmaceutical sector.

To discover more about PTC Therapeutics and its initiatives, stakeholders are encouraged to visit their official website at www.ptcbio.com and connect with them on LinkedIn, X, Instagram, and Facebook.

Conclusion

The recent inducement grants made by PTC Therapeutics reflect a proactive approach to workforce development, ensuring the company remains competitive in attracting skilled professionals who can contribute to its mission of transforming healthcare for individuals with rare disorders. This strategic initiative showcases PTC's commitment to fostering a culture of growth and reward for its employees, paving the way for future success in the biopharmaceutical industry.